Compare
Amgen vs Roivant Sciences (AMGN vs ROIV)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Roivant Sciences (ROIV) +92.2%; so far this year the figures are +40.7% and +79.2%.
Amgen is the larger company by market value, about 8.9 times the size of Roivant Sciences.
Revenue grew +8.2% at AMGN and -67.6% at ROIV over the last year.
AMGN yields 2.16%. ROIV pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | ROIV | |
|---|---|---|
| Price | $460.42 | $38.88 |
| 1-day | +0.03% | +6.17% |
| YTD | +40.67% | +79.17% |
| 1 year | +43.94% | +92.19% |
| 3 years | +76.51% | +329.14% |
| Market cap | $249.1B | $28.1B |
| P/E | 26.7 | — |
| P/S | 6.40 | 3,728.61 |
| P/B | 17.35 | 6.64 |
| Revenue growth | +8.20% | -67.60% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | -3,535.0 |
| ROE % | 65.4 | -6.3 |
| Debt / equity | 3.76 | 0.08 |
| FCF yield % | 3.8 | -3.0 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 1.09 |
| RSI (14) | 60.5 | 59.8 |
| Technical rating |